Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

The two largest leases in Boston-Cambridge's life science market went to Korro Bio and Ultragenyx Pharmaceuticals, which ...

Quotient Therapeutics, a biotech company founded in 2022, hopes to take this transatlantic model and commercialise it. Its main research lab is in Great Chesterford, a village just outside Cambridge, ...

Our pharma partners in the Milner Therapeutics Consortium have identified topics for challenges that are a current priority for external collaboration with academics. These projects could provide a ...

The 2025 Milner Therapeutics Consortium Call opened on 13 January, with an exciting new focus around pharma-led challenges. The 2025 Milner Therapeutics Consortium Call opened on 13 January, with an ...

Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. Teoxane ...

Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...

CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from ...